Invivo Therapeutics (NASDAQ:NVIV) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Thursday.
Shares of NVIV stock traded down $0.06 on Thursday, hitting $1.40. 30,400 shares of the company’s stock traded hands, compared to its average volume of 163,501. Invivo Therapeutics has a one year low of $1.36 and a one year high of $24.75. The firm has a market cap of $13.49 million, a P/E ratio of -0.08 and a beta of 1.76.
Invivo Therapeutics (NASDAQ:NVIV) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.42) EPS for the quarter. As a group, equities analysts predict that Invivo Therapeutics will post -11.58 earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in NVIV. Renaissance Technologies LLC bought a new stake in Invivo Therapeutics in the 2nd quarter worth $211,000. Stonepine Capital Management LLC bought a new stake in Invivo Therapeutics in the 2nd quarter worth $132,000. Vanguard Group Inc. grew its holdings in Invivo Therapeutics by 358.4% in the 3rd quarter. Vanguard Group Inc. now owns 86,088 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 67,307 shares during the last quarter. Vanguard Group Inc grew its holdings in Invivo Therapeutics by 358.4% in the 3rd quarter. Vanguard Group Inc now owns 86,088 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 67,307 shares during the last quarter. Finally, IMS Capital Management grew its holdings in Invivo Therapeutics by 27.4% in the 3rd quarter. IMS Capital Management now owns 31,754 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 6,838 shares during the last quarter. 5.79% of the stock is currently owned by institutional investors and hedge funds.
About Invivo Therapeutics
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.
Featured Article: Return on Equity (ROE)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Invivo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Invivo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.